<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00190749</url>
  </required_header>
  <id_info>
    <org_study_id>5296</org_study_id>
    <secondary_id>F1D-MC-S014</secondary_id>
    <nct_id>NCT00190749</nct_id>
  </id_info>
  <brief_title>Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder</brief_title>
  <official_title>Insulin Sensitivity in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Risperidone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess whether olanzapine and/or risperidone affect the way the human body
      uses sugar in the blood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Baseline to Last Observation In Normalized Insulin Sensitivity Index at Low Insulin Phase Using Change in Weight as a Covariate</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Normalized insulin sensitivity index (Mffm/I) was defined as the ratio of whole body glucose disposal rate normalized to fat-free mass (Mffm) divided by the plasma insulin concentration (I) during steady-state conditions of the clamp procedure. Units:[(mg glucose)*min*mL] / [(kg fat free body mass)*(micro IU insulin)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Weight.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Body Mass Index (BMI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Ratio of Visceral Fat Area to the Subcutaneous Fat Area.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in ratio of visceral far area to subcutaneous fat area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Brief Psychiatric Rating Scale Scores.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Normalized insulin senstivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in Brief Psychiatric Rating Scale scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Clinical Global Impression - Severity of Illness Scale Scores.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in Clinical Global Impression-Severity of Illness scale scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Abnormal Involuntary Movement Scale Scores.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in Abnormal Involuntary Movement Scale scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pairwise Correlation Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Barnes Akathisia Scale Scores.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in Barnes Akathisia scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in the Simpson Angus Scale Scores.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in the Simpson Angus Scale scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Waist Circumference.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in waist circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Visceral Fat Area.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in visceral fat area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Subcutaneous Fat Area.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in subcutaneous fat area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pairwise Correlations Between Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Eating Behavior Assessment Scale Scores.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in Eating Behavior Assessment Scale scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Body Mass Index</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Within-and Between-Treatment Group changes in Body Mass Index from baseline to last observation carried forward.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Weight</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Weight change from baseline to last visit (last observation carried forward)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Waist Circumference</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Waist circumference change from baseline to last observation carried forward.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Visceral Fat Area</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Visceral fat area change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Subcutaneous Fat Area</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Subcutaneous fat area change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in the Ratio of the Visceral Fat Area to the Subcutaneous Fat Area</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Ratio of the visceral fat area to the subcutaneous fat area change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Brief Psychiatric Rating Scale (BPRS) Scores</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Brief Psychiatric Rating Scale (BPRS) is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Item scores range from 0 (not present) to 6 (extremely severe). Total Scores range from 0 to 108; Positive Subscale Scores range from 0 to 24. Negative Subscale Scores range from 0 to 18. Anxiety-Depression Subscale Scores range from 0 to 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Clinical Global Impression - Severity of Illness Scores</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Abnormal Involuntary Movement Scale Scores</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>A 12-item instrument assesses observed abnormal movements in different parts of body. Seven items are scored in a 5-point scale (0 = none/normal, 4 = severe) which evaluates abnormal movements in 3 main anatomic areas (orofacial area, extremities, and trunk). Total scores range from 0 to 28. Five collected elements are not used in this total.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Barnes Akathisia Rating Scale (BARS) Scores</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>The BARS is a 4-item instrument that evaluates akathisia associated with use of antipsychotic medications. Item 4 is the Global clinical assessment and is rated 0 to 5 (0 = absent, 5 = severe). The other 3 items (related to objective and subjective assessments) are not used for these analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Simpson Angus Scale Scores</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Measures neuroleptic-induced parkinsonism. Total score of Simpson Angus Scale consists of the sum of 10 items rated on a 5-point severity scale where 0=normal and 4=extreme. The total score ranges from 0 to 40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Eating Behavior Assessment Scale Scores</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Eating Behavior Assessment Scale is a 9-item self-rated tool used to evaluate appetite and eating behaviors. Item scores range from 0 (never) to 4 (always).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Fasting Lipid Parameters Including Total Cholesterol</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Fasting lipid parameters including total cholesterol, change from baseline to last observation carried forward.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Fasting Lipid Parameters Including Direct Low Density Lipoprotein (LDL)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Fasting lipid parameters including Direct LDL, change from baseline to last observation carried forward.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Fasting Lipid Parameters Including High Density Lipoprotein (HDL)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Fasting lipid parameters including HDL change from baseline to last observation carried forward.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Fasting Lipid Parameters Including Triglycerides</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Changes in fasting lipid parameters including triglycerides last observation carried forward (LOCF) mean change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Fasting Lipid Parameters Including Lipoprotein Subclasses</measure>
    <time_frame>baseline and 12 weeks.</time_frame>
    <description>Changes in lipid parameters and subclass lipoproteins last observation carried forward (LOCF) mean change from baseline. HDL=High Density Lipoprotein, IDL=Intermdiate Density Lipoprotein, LDL=Low Density Lipoprotein, VLDL=Very Low Density Lipoprotein.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>5-20 mg, oral, capsules, daily, 12 weeks.</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <other_name>LY170053</other_name>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risperidone</intervention_name>
    <description>2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
    <arm_group_label>Risperidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years old

          -  Diagnosed with Schizophrenia or Schizoaffective disorder

          -  Ability to visit the doctor's office for scheduled visits

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Have a body mass index (BMI) greater than 40

          -  Have diabetes, heart disease or any other unstable illness

          -  Have known positive human immunodeficiency virus (HIV)

          -  Are currently taking olanzapine, risperidone, clozapine, glucocorticoids, injectable
             antipsychotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <results_first_submitted>June 3, 2009</results_first_submitted>
  <results_first_submitted_qc>June 3, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 23, 2009</results_first_posted>
  <last_update_submitted>April 26, 2010</last_update_submitted>
  <last_update_submitted_qc>April 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study Period I was a Screening Period. Study Period II was a Inpatient Washout/Diet Stabilization Period. Study Period III (randomization) was the Double-Blind Therapy Period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Olanzapine</title>
          <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Risperidone</title>
          <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olanzapine</title>
          <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Risperidone</title>
          <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="62"/>
            <count group_id="B3" value="130"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.49" spread="9.45"/>
                    <measurement group_id="B2" value="42.58" spread="8.98"/>
                    <measurement group_id="B3" value="43.06" spread="9.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Schizophrenia,paranoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Schizoaffective disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Schizophrenia, undifferentiated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African descent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Brief Psychiatric Rating Scale Anxiety Depression Score-Baseline</title>
          <description>Brief Psychiatric Rating Scale (BPRS) Anxiety-Depression Score assesses the degree of severity of a subject's anxiety-depression symptoms. BPRS Anxiety-Depression Score is the sum of Item Scores 1, 2, 5 and 9. Item scores range from 0 (not present) to 6 (extremely severe). Total Scores for Anxiety-Depression range from 0 to 24.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.46" spread="2.46"/>
                    <measurement group_id="B2" value="3.74" spread="2.13"/>
                    <measurement group_id="B3" value="4.12" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Brief Psychiatric Rating Scale Negative Symptom Score-Baseline</title>
          <description>Brief Psychiatric Rating Scale (BPRS) Negative Score assesses the degree of severity of a subject's negative symptoms. BPRS Negative Score is the sum of Item Scores 3, 13, and 16. Item scores range from 0 (not present) to 6 (extremely severe). Total Scores for Negative Score range from 0 to 18.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.28" spread="1.98"/>
                    <measurement group_id="B2" value="1.89" spread="1.79"/>
                    <measurement group_id="B3" value="2.09" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Brief Psychiatric Rating Scale Positive Symptom Score-Baseline</title>
          <description>Brief Psychiatric Rating Scale (BPRS) Positive Score assesses the degree of severity of a subject's positive symptoms. BPRS Positive Score is the sum of Item Scores 4, 11, 12, and 15. Item scores range from 0 (not present) to 6 (extremely severe). Total Scores for Positive Score range from 0 to 24.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.40" spread="2.69"/>
                    <measurement group_id="B2" value="5.47" spread="2.52"/>
                    <measurement group_id="B3" value="5.43" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Brief Psychiatric Rating Scale Total Score-Baseline</title>
          <description>Brief Psychiatric Rating Scale (BPRS) Total Score is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Item scores range from 0 (not present) to 6 (extremely severe). Total Scores range from 0 to 108.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.63" spread="6.06"/>
                    <measurement group_id="B2" value="14.29" spread="6.00"/>
                    <measurement group_id="B3" value="14.99" spread="6.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impression Severity Score- Baseline</title>
          <description>Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.68" spread="0.56"/>
                    <measurement group_id="B2" value="3.65" spread="0.52"/>
                    <measurement group_id="B3" value="3.66" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Extrapyramidal Scores/Abnormal Involuntary Movement-Baseline</title>
          <description>A 12-item instrument assesses observed abnormal movements in different parts of body. Seven items are scored in a 5-point scale (0 = none/normal, 4 = severe) which evaluates abnormal movements in 3 main anatomic areas (orofacial area, extremities, and trunk). Total scores range from 0 to 28. Five collected elements are not used in this total.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.42" spread="1.14"/>
                    <measurement group_id="B2" value="0.47" spread="1.13"/>
                    <measurement group_id="B3" value="0.44" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Extrapyramidal Scores/Barnes Akathisia Rating Scale (BARS) Global Clinical Assessment-Baseline</title>
          <description>The BARS is a 4-item instrument that evaluates akathisia associated with use of antipsychotic medications. Item 4 is the Global clinical assessment and is rated 0 to 5 (0 = absent, 5 = severe).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.27" spread="0.66"/>
                    <measurement group_id="B2" value="0.32" spread="0.67"/>
                    <measurement group_id="B3" value="0.29" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Extrapyramidal Scores/Simpson-Angus-Baseline</title>
          <description>Measures neuroleptic-induced parkinsonism. Total score of Simpson Angus Scale consists of the sum of 10 itemsrated on a 5-point severity scale where 0=normal and 4=extreme. The total score ranges from 0 to 40.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.97" spread="1.87"/>
                    <measurement group_id="B2" value="0.90" spread="1.80"/>
                    <measurement group_id="B3" value="0.94" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Baseline to Last Observation In Normalized Insulin Sensitivity Index at Low Insulin Phase Using Change in Weight as a Covariate</title>
        <description>Normalized insulin sensitivity index (Mffm/I) was defined as the ratio of whole body glucose disposal rate normalized to fat-free mass (Mffm) divided by the plasma insulin concentration (I) during steady-state conditions of the clamp procedure. Units:[(mg glucose)*min*mL] / [(kg fat free body mass)*(micro IU insulin)]</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>N=number of patients with a baseline and post-baseline result within each treatment group for Mffm/I and weight.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Baseline to Last Observation In Normalized Insulin Sensitivity Index at Low Insulin Phase Using Change in Weight as a Covariate</title>
          <description>Normalized insulin sensitivity index (Mffm/I) was defined as the ratio of whole body glucose disposal rate normalized to fat-free mass (Mffm) divided by the plasma insulin concentration (I) during steady-state conditions of the clamp procedure. Units:[(mg glucose)*min*mL] / [(kg fat free body mass)*(micro IU insulin)]</description>
          <population>N=number of patients with a baseline and post-baseline result within each treatment group for Mffm/I and weight.</population>
          <units>Mffm/I</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1664" spread="0.1120"/>
                    <measurement group_id="O2" value="0.1937" spread="0.1286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0149" spread="0.0786"/>
                    <measurement group_id="O2" value="-0.0327" spread="0.0829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.226</p_value>
            <p_value_desc>P-value for change to last observation</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.030</p_value>
            <p_value_desc>P-value is change to last observation</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.204</p_value>
            <p_value_desc>P-value for change to last observation.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Weight.</title>
        <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in weight</description>
        <time_frame>12 weeks</time_frame>
        <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Weight.</title>
          <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in weight</description>
          <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
          <units>correlation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.212"/>
                    <measurement group_id="O2" value="-0.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.184</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.295</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Body Mass Index (BMI)</title>
        <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in BMI</description>
        <time_frame>12 weeks</time_frame>
        <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Body Mass Index (BMI)</title>
          <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in BMI</description>
          <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
          <units>correlation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.182"/>
                    <measurement group_id="O2" value="-0.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.256</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.277</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Ratio of Visceral Fat Area to the Subcutaneous Fat Area.</title>
        <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in ratio of visceral far area to subcutaneous fat area</description>
        <time_frame>12 weeks</time_frame>
        <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Ratio of Visceral Fat Area to the Subcutaneous Fat Area.</title>
          <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in ratio of visceral far area to subcutaneous fat area</description>
          <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
          <units>correlation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.055"/>
                    <measurement group_id="O2" value="0.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.766</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.622</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Brief Psychiatric Rating Scale Scores.</title>
        <description>Normalized insulin senstivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in Brief Psychiatric Rating Scale scores</description>
        <time_frame>12 weeks</time_frame>
        <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Brief Psychiatric Rating Scale Scores.</title>
          <description>Normalized insulin senstivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in Brief Psychiatric Rating Scale scores</description>
          <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
          <units>correlation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.035"/>
                    <measurement group_id="O2" value="0.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.829</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.714</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Clinical Global Impression - Severity of Illness Scale Scores.</title>
        <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in Clinical Global Impression-Severity of Illness scale scores</description>
        <time_frame>12 weeks</time_frame>
        <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Clinical Global Impression - Severity of Illness Scale Scores.</title>
          <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in Clinical Global Impression-Severity of Illness scale scores</description>
          <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
          <units>correlation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.068"/>
                    <measurement group_id="O2" value="0.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.672</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.191</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Abnormal Involuntary Movement Scale Scores.</title>
        <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in Abnormal Involuntary Movement Scale scores</description>
        <time_frame>12 weeks</time_frame>
        <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Abnormal Involuntary Movement Scale Scores.</title>
          <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in Abnormal Involuntary Movement Scale scores</description>
          <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
          <units>correlation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001"/>
                    <measurement group_id="O2" value="-0.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.994</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.456</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pairwise Correlation Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Barnes Akathisia Scale Scores.</title>
        <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in Barnes Akathisia scores</description>
        <time_frame>12 weeks</time_frame>
        <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pairwise Correlation Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Barnes Akathisia Scale Scores.</title>
          <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in Barnes Akathisia scores</description>
          <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
          <units>correlation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.120"/>
                    <measurement group_id="O2" value="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.454</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.974</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in the Simpson Angus Scale Scores.</title>
        <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in the Simpson Angus Scale scores</description>
        <time_frame>12 weeks</time_frame>
        <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in the Simpson Angus Scale Scores.</title>
          <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in the Simpson Angus Scale scores</description>
          <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
          <units>correlation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.184"/>
                    <measurement group_id="O2" value="0.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.249</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.163</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Waist Circumference.</title>
        <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in waist circumference</description>
        <time_frame>12 weeks</time_frame>
        <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Waist Circumference.</title>
          <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in waist circumference</description>
          <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations</population>
          <units>correlation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.206"/>
                    <measurement group_id="O2" value="-0.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.201</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.168</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Visceral Fat Area.</title>
        <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in visceral fat area</description>
        <time_frame>12 weeks</time_frame>
        <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Visceral Fat Area.</title>
          <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in visceral fat area</description>
          <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations</population>
          <units>correlation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.048"/>
                    <measurement group_id="O2" value="-0.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.793</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.777</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Subcutaneous Fat Area.</title>
        <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in subcutaneous fat area</description>
        <time_frame>12 weeks</time_frame>
        <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pairwise Correlations Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Subcutaneous Fat Area.</title>
          <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in subcutaneous fat area</description>
          <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
          <units>correlation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.043"/>
                    <measurement group_id="O2" value="-0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.815</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.675</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pairwise Correlations Between Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Eating Behavior Assessment Scale Scores.</title>
        <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in Eating Behavior Assessment Scale scores</description>
        <time_frame>12 weeks</time_frame>
        <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pairwise Correlations Between Between Changes in Normalized Insulin Sensitivity Index at Low Insulin Phase and Changes in Eating Behavior Assessment Scale Scores.</title>
          <description>Normalized insulin sensitivity index (Mffm/I) at low insulin phase-pairwise correlations between changes in Mffm/I and changes in Eating Behavior Assessment Scale scores</description>
          <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
          <units>correlation</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Item 1: How Hungry?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.137"/>
                    <measurement group_id="O2" value="-0.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 2: How Strong Appetite?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.137"/>
                    <measurement group_id="O2" value="-0.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 3: Craved Sweets or Other Carbohydrates?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.009"/>
                    <measurement group_id="O2" value="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 4: Craved Fatty Foods?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.068"/>
                    <measurement group_id="O2" value="-0.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 5: Felt Full or Satisfied After Meal?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.117"/>
                    <measurement group_id="O2" value="-0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 6:Excessive Amount of Food to Feel Satisfied?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.134"/>
                    <measurement group_id="O2" value="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 7: Thinking About Food?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.172"/>
                    <measurement group_id="O2" value="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 8: Overeating?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.032"/>
                    <measurement group_id="O2" value="-0.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 9: Feel Eating is Out of Control?</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.075"/>
                    <measurement group_id="O2" value="-0.354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in Eating Behavior Item 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.393</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Eating Behavior Item 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in Eating Behavior Item 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.392</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Eating Behavior Item 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.129</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in Eating Bahavior Item 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.956</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Eating Behavior Item 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.846</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in Eating Behavior Item 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.675</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Eating Behavior Item 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.306</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in Eating Behavior Item 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.468</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Eating Behavior Item 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.739</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in Eating Behavior Item 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.404</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Eating Behavior Item 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.711</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in Eating Behavior Item 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.281</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Eating Behavior Item 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.805</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in Eating Behavior Item 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.844</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Eating Bahavior Item 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.359</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in Eating Behavior Item 9</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.642</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Eating Behavior Item 9</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>Pearson's correlation coefficient</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Body Mass Index</title>
        <description>Within-and Between-Treatment Group changes in Body Mass Index from baseline to last observation carried forward.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Body Mass Index</title>
          <description>Within-and Between-Treatment Group changes in Body Mass Index from baseline to last observation carried forward.</description>
          <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations</population>
          <units>kilograms per square meter (kg/m2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.96" spread="5.17"/>
                    <measurement group_id="O2" value="28.79" spread="5.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="1.61"/>
                    <measurement group_id="O2" value="0.39" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on Least Squares Mean (LSMean) change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.065</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change =Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Weight</title>
        <description>Weight change from baseline to last visit (last observation carried forward)</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Weight</title>
          <description>Weight change from baseline to last visit (last observation carried forward)</description>
          <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.93" spread="17.26"/>
                    <measurement group_id="O2" value="86.55" spread="19.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" spread="4.82"/>
                    <measurement group_id="O2" value="1.23" spread="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>With group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.076</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change = Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Waist Circumference</title>
        <description>Waist circumference change from baseline to last observation carried forward.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Waist Circumference</title>
          <description>Waist circumference change from baseline to last observation carried forward.</description>
          <population>Randomized patients who completed the baseline and endpoint clamps with both diet stabilizations.</population>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.13" spread="14.42"/>
                    <measurement group_id="O2" value="98.49" spread="11.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="7.46"/>
                    <measurement group_id="O2" value="0.17" spread="4.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.266</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.239</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change = Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Visceral Fat Area</title>
        <description>Visceral fat area change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Abdominal CT scan of changes from baseline to last observation of randomized patients who completed baseline and endpoint clamps with both diet stabilizations</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Visceral Fat Area</title>
          <description>Visceral fat area change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</description>
          <population>Abdominal CT scan of changes from baseline to last observation of randomized patients who completed baseline and endpoint clamps with both diet stabilizations</population>
          <units>square centimeters (cm2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.46" spread="54.99"/>
                    <measurement group_id="O2" value="102.17" spread="52.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.70" spread="21.21"/>
                    <measurement group_id="O2" value="8.70" spread="42.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.274</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-vales are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.105</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.609</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change= Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Subcutaneous Fat Area</title>
        <description>Subcutaneous fat area change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Abdominal CT scan change from baseline to last observation for randomized patients who completed baseline and endpoint clamps with both diet stabilizations</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Subcutaneous Fat Area</title>
          <description>Subcutaneous fat area change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</description>
          <population>Abdominal CT scan change from baseline to last observation for randomized patients who completed baseline and endpoint clamps with both diet stabilizations</population>
          <units>square centimeters (cm2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281.07" spread="158.59"/>
                    <measurement group_id="O2" value="317.16" spread="172.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to last observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.94" spread="40.36"/>
                    <measurement group_id="O2" value="35.15" spread="105.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.406</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>With group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.076</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall group p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in the Ratio of the Visceral Fat Area to the Subcutaneous Fat Area</title>
        <description>Ratio of the visceral fat area to the subcutaneous fat area change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Abdominal CT scan change from baseline to last observation of randomized patients who completed the baseline and endpoint clamps with both diet stabilizations</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in the Ratio of the Visceral Fat Area to the Subcutaneous Fat Area</title>
          <description>Ratio of the visceral fat area to the subcutaneous fat area change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</description>
          <population>Abdominal CT scan change from baseline to last observation of randomized patients who completed the baseline and endpoint clamps with both diet stabilizations</population>
          <units>ratio in square centimeters (cm2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.25"/>
                    <measurement group_id="O2" value="0.43" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to last observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.12"/>
                    <measurement group_id="O2" value="0.00" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.456</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.712</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.689</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change= Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Brief Psychiatric Rating Scale (BPRS) Scores</title>
        <description>Brief Psychiatric Rating Scale (BPRS) is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Item scores range from 0 (not present) to 6 (extremely severe). Total Scores range from 0 to 108; Positive Subscale Scores range from 0 to 24. Negative Subscale Scores range from 0 to 18. Anxiety-Depression Subscale Scores range from 0 to 24.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>BPRS Total and Subscale Scores-Change from Baseline to Last Observation Carried Forward, all randomized patients, double-blind treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Brief Psychiatric Rating Scale (BPRS) Scores</title>
          <description>Brief Psychiatric Rating Scale (BPRS) is an 18-item clinician-administered scale used to assess the degree of severity of a subject's general psychopathological symptoms. Item scores range from 0 (not present) to 6 (extremely severe). Total Scores range from 0 to 108; Positive Subscale Scores range from 0 to 24. Negative Subscale Scores range from 0 to 18. Anxiety-Depression Subscale Scores range from 0 to 24.</description>
          <population>BPRS Total and Subscale Scores-Change from Baseline to Last Observation Carried Forward, all randomized patients, double-blind treatment period</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Score Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.32" spread="6.26"/>
                    <measurement group_id="O2" value="13.96" spread="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Score Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.98" spread="6.30"/>
                    <measurement group_id="O2" value="-1.48" spread="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive Subscale Score Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.22" spread="2.75"/>
                    <measurement group_id="O2" value="5.27" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive Subscale Score Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="2.81"/>
                    <measurement group_id="O2" value="-1.20" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Subscale Score Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="2.04"/>
                    <measurement group_id="O2" value="1.88" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Subscale Score Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="1.58"/>
                    <measurement group_id="O2" value="-0.02" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety-Depression Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="2.59"/>
                    <measurement group_id="O2" value="3.73" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety-Depression Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="2.29"/>
                    <measurement group_id="O2" value="-0.32" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Total Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.111</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.159</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean changes</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total Score</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.951</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change =Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Positive Subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Positive subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>With group p-values are from t-tests on LSMean</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Positive subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.467</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change =Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Negative subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.365</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>With group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Negative subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.846</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Negative subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.559</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Anxiety-Depression subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.150</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anxiety-Depression subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.612</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anxiety-Depression subscale</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.475</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Clinical Global Impression - Severity of Illness Scores</title>
        <description>Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Clinical Global Impression - Severity of Illness Scores</title>
          <description>Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients.</description>
          <population>Change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.65" spread="0.55"/>
                    <measurement group_id="O2" value="3.61" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to last observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.58"/>
                    <measurement group_id="O2" value="-0.23" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.012</p_value>
            <p_value_desc>Within group p-values are from t-tests on LSMean change</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.760</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of square ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Abnormal Involuntary Movement Scale Scores</title>
        <description>A 12-item instrument assesses observed abnormal movements in different parts of body. Seven items are scored in a 5-point scale (0 = none/normal, 4 = severe) which evaluates abnormal movements in 3 main anatomic areas (orofacial area, extremities, and trunk). Total scores range from 0 to 28. Five collected elements are not used in this total.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Abnormal Involuntary Movement Scale Scores</title>
          <description>A 12-item instrument assesses observed abnormal movements in different parts of body. Seven items are scored in a 5-point scale (0 = none/normal, 4 = severe) which evaluates abnormal movements in 3 main anatomic areas (orofacial area, extremities, and trunk). Total scores range from 0 to 28. Five collected elements are not used in this total.</description>
          <population>Change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="1.24"/>
                    <measurement group_id="O2" value="0.53" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to last observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="1.15"/>
                    <measurement group_id="O2" value="0.04" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.943</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.763</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.832</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Barnes Akathisia Rating Scale (BARS) Scores</title>
        <description>The BARS is a 4-item instrument that evaluates akathisia associated with use of antipsychotic medications. Item 4 is the Global clinical assessment and is rated 0 to 5 (0 = absent, 5 = severe). The other 3 items (related to objective and subjective assessments) are not used for these analyses.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Barnes Akathisia Rating Scale (BARS) Scores</title>
          <description>The BARS is a 4-item instrument that evaluates akathisia associated with use of antipsychotic medications. Item 4 is the Global clinical assessment and is rated 0 to 5 (0 = absent, 5 = severe). The other 3 items (related to objective and subjective assessments) are not used for these analyses.</description>
          <population>Change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.64"/>
                    <measurement group_id="O2" value="0.36" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to last observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.84"/>
                    <measurement group_id="O2" value="-0.02" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.623</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.853</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.591</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Simpson Angus Scale Scores</title>
        <description>Measures neuroleptic-induced parkinsonism. Total score of Simpson Angus Scale consists of the sum of 10 items rated on a 5-point severity scale where 0=normal and 4=extreme. The total score ranges from 0 to 40.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Simpson Angus Scale Scores</title>
          <description>Measures neuroleptic-induced parkinsonism. Total score of Simpson Angus Scale consists of the sum of 10 items rated on a 5-point severity scale where 0=normal and 4=extreme. The total score ranges from 0 to 40.</description>
          <population>Change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="2.02"/>
                    <measurement group_id="O2" value="0.94" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to last observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="1.48"/>
                    <measurement group_id="O2" value="0.30" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.302</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.922</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.479</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall group p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Eating Behavior Assessment Scale Scores</title>
        <description>Eating Behavior Assessment Scale is a 9-item self-rated tool used to evaluate appetite and eating behaviors. Item scores range from 0 (never) to 4 (always).</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Eating Behavior Assessment Scale Scores</title>
          <description>Eating Behavior Assessment Scale is a 9-item self-rated tool used to evaluate appetite and eating behaviors. Item scores range from 0 (never) to 4 (always).</description>
          <population>Change from baseline to last observation carried forward, all randomized patients, double-blind treatment period</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Item 1 Baseline (How Hungry?)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="1.09"/>
                    <measurement group_id="O2" value="1.32" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 1 Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="1.27"/>
                    <measurement group_id="O2" value="0.42" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 2 Baseline (How Strong Appetite?)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="1.10"/>
                    <measurement group_id="O2" value="1.32" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 2 Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="1.26"/>
                    <measurement group_id="O2" value="0.38" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 3 Baseline (Craved Sweets or Other Carbos?)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="1.17"/>
                    <measurement group_id="O2" value="0.83" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 3 Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="1.47"/>
                    <measurement group_id="O2" value="0.36" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 4 Baseline (Craved Fatty Foods?)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="1.01"/>
                    <measurement group_id="O2" value="0.74" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 4 Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="1.52"/>
                    <measurement group_id="O2" value="0.25" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 5 Baseline (Felt Full After Meal?)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="0.93"/>
                    <measurement group_id="O2" value="2.55" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 5 Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="1.15"/>
                    <measurement group_id="O2" value="0.00" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 6 Baseline(Excessive Food to Feel Satisfied?)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="1.21"/>
                    <measurement group_id="O2" value="0.79" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 6 Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="1.40"/>
                    <measurement group_id="O2" value="0.28" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 7 Baseline (Thinking About Food?)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="1.18"/>
                    <measurement group_id="O2" value="0.77" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 7 Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="1.31"/>
                    <measurement group_id="O2" value="0.13" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 8 Baseline (Overeating?)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.95"/>
                    <measurement group_id="O2" value="0.53" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 8 Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="1.33"/>
                    <measurement group_id="O2" value="0.15" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 9 Baseline (Feel Eating is Out of Control?)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.36"/>
                    <measurement group_id="O2" value="0.26" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Item 9 Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.94"/>
                    <measurement group_id="O2" value="0.11" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Item 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Item 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Item 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.549</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares, ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Item 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Item 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Item 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.793</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Item 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.045</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Item 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Item 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.699</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Item 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ITem 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Item 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.733</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Item 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Item 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.235</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Item 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.532</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Item 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.242</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Item 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.186</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Item 6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.799</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Item 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.097</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Item 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.214</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Item 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.827</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Item 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.151</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Item 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.071</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Item 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.629</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Item 9</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Item 9</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.112</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Item 9</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.806</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Fasting Lipid Parameters Including Total Cholesterol</title>
        <description>Fasting lipid parameters including total cholesterol, change from baseline to last observation carried forward.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Change from baseline to last observation, all randomized patients, double-blind treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Fasting Lipid Parameters Including Total Cholesterol</title>
          <description>Fasting lipid parameters including total cholesterol, change from baseline to last observation carried forward.</description>
          <population>Change from baseline to last observation, all randomized patients, double-blind treatment period</population>
          <units>millimoles per Liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.91" spread="1.06"/>
                    <measurement group_id="O2" value="4.97" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.89"/>
                    <measurement group_id="O2" value="0.01" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.156</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.829</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.352</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Fasting Lipid Parameters Including Direct Low Density Lipoprotein (LDL)</title>
        <description>Fasting lipid parameters including Direct LDL, change from baseline to last observation carried forward.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Change from baseline to last observation, all randomized patients, double-blind treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Fasting Lipid Parameters Including Direct Low Density Lipoprotein (LDL)</title>
          <description>Fasting lipid parameters including Direct LDL, change from baseline to last observation carried forward.</description>
          <population>Change from baseline to last observation, all randomized patients, double-blind treatment period</population>
          <units>millimoles per Liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.18" spread="0.90"/>
                    <measurement group_id="O2" value="3.11" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to last observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.67"/>
                    <measurement group_id="O2" value="-0.02" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.740</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.760</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are frm t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.997</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Fasting Lipid Parameters Including High Density Lipoprotein (HDL)</title>
        <description>Fasting lipid parameters including HDL change from baseline to last observation carried forward.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Change from baseline to last observation, all randomized patients, double-blind treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Fasting Lipid Parameters Including High Density Lipoprotein (HDL)</title>
          <description>Fasting lipid parameters including HDL change from baseline to last observation carried forward.</description>
          <population>Change from baseline to last observation, all randomized patients, double-blind treatment period</population>
          <units>millimoles per Liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.25"/>
                    <measurement group_id="O2" value="1.18" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to last observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.24"/>
                    <measurement group_id="O2" value="0.05" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.176</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.237</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.996</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Fasting Lipid Parameters Including Triglycerides</title>
        <description>Changes in fasting lipid parameters including triglycerides last observation carried forward (LOCF) mean change from baseline</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Change from baseline to last observation, all randomized patients, double-blind treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Fasting Lipid Parameters Including Triglycerides</title>
          <description>Changes in fasting lipid parameters including triglycerides last observation carried forward (LOCF) mean change from baseline</description>
          <population>Change from baseline to last observation, all randomized patients, double-blind treatment period</population>
          <units>millimoles per Liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.91"/>
                    <measurement group_id="O2" value="1.55" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to Last Observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="1.12"/>
                    <measurement group_id="O2" value="-0.10" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.545</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Fasting Lipid Parameters Including Lipoprotein Subclasses</title>
        <description>Changes in lipid parameters and subclass lipoproteins last observation carried forward (LOCF) mean change from baseline. HDL=High Density Lipoprotein, IDL=Intermdiate Density Lipoprotein, LDL=Low Density Lipoprotein, VLDL=Very Low Density Lipoprotein.</description>
        <time_frame>baseline and 12 weeks.</time_frame>
        <population>Mean change from baseline, all randomized patients, double-blind treatment period</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Fasting Lipid Parameters Including Lipoprotein Subclasses</title>
          <description>Changes in lipid parameters and subclass lipoproteins last observation carried forward (LOCF) mean change from baseline. HDL=High Density Lipoprotein, IDL=Intermdiate Density Lipoprotein, LDL=Low Density Lipoprotein, VLDL=Very Low Density Lipoprotein.</description>
          <population>Mean change from baseline, all randomized patients, double-blind treatment period</population>
          <units>nanomoles per Liter (nmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HDL particles, total, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.39" spread="5.38"/>
                    <measurement group_id="O2" value="29.81" spread="5.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL particles, total, change to last observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="4.84"/>
                    <measurement group_id="O2" value="-1.09" spread="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IDL, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.18" spread="55.32"/>
                    <measurement group_id="O2" value="52.56" spread="61.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IDL, change to last observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.40" spread="59.63"/>
                    <measurement group_id="O2" value="-2.69" spread="46.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium small LDL, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.15" spread="98.59"/>
                    <measurement group_id="O2" value="197.00" spread="116.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium small LDL, change to last observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.70" spread="52.40"/>
                    <measurement group_id="O2" value="-11.47" spread="84.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small LDL, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="878.68" spread="481.65"/>
                    <measurement group_id="O2" value="977.84" spread="622.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small LDL, change to last observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.55" spread="236.89"/>
                    <measurement group_id="O2" value="-74.09" spread="428.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very small LDL, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="703.63" spread="385.31"/>
                    <measurement group_id="O2" value="780.78" spread="508.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very small LDL, change to last observation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.75" spread="193.00"/>
                    <measurement group_id="O2" value="-62.50" spread="347.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL mean particle size, baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.21" spread="8.57"/>
                    <measurement group_id="O2" value="51.05" spread="11.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL mean particle size, change to last observ.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" spread="7.83"/>
                    <measurement group_id="O2" value="1.80" spread="9.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>HDL particles, total</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HDL particles, total</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.959</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>HDL particles, total</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <p_value_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline TReatment Pooled Investigator</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>IDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>IDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.928</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>IDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Medium small LDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Medium small LDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.662</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Medium small LDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Small LDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.099</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Small LDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.304</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Small LDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Very small LDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.176</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Very small LDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.246</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Withn group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Very small LDL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <p_value_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>VLDL mean particle size</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>VLDL mean particle size</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Within group p-values are from t-tests on LSMean change</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>VLDL mean particle size</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.221</p_value>
            <method>ANCOVA</method>
            <method_desc>Overall p-values are from Type 3 sums of squares ANCOVA, Model: Change=Baseline Treatment Pooled Investigator</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Olanzapine</title>
          <description>Olanzapine, 5-20 mg, oral, capsules, daily, 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Risperidone</title>
          <description>Risperidone, 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="68"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

